112946-34-6

Basic information

• Product Name: rel-(1S,3aR,4R,7aS)-Methyl 1-<2-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,5,6,7,7a-octahydro-4-hydroxy-4-<(2,5-dimethoxyphenyl)methyl>-3aH-indene-1-carboxylate
• Synonyms: rel-(1S,3aR,4R,7aS)-Methyl 1-<2-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,5,6,7,7a-octahydro-4-hydroxy-4-<(2,5-dimethoxyphenyl)methyl>-3aH-indene-1-carboxylate
• CAS NO: 112946-34-6
• Molecular Weight: 520.782
• Mol File: 112946-34-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: rel-(1S,3aR,4R,7aS)-Methyl 1-<2-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,5,6,7,7a-octahydro-4-hydroxy-4-<(2,5-dimethoxyphenyl)methyl>-3aH-indene-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: rel-(1S,3aR,4R,7aS)-Methyl 1-<2-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,5,6,7,7a-octahydro-4-hydroxy-4-<(2,5-dimethoxyphenyl)methyl>-3aH-indene-1-carboxylate(112946-34-6)
• EPA Substance Registry System: rel-(1S,3aR,4R,7aS)-Methyl 1-<2-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,5,6,7,7a-octahydro-4-hydroxy-4-<(2,5-dimethoxyphenyl)methyl>-3aH-indene-1-carboxylate(112946-34-6)

Safety Data

• Hazardous Substances Data: 112946-34-6(Hazardous Substances Data)

Upstream product

• 99474-50-7 rel-(1S,3aS,7R,7aS)-Ethyl 1,2,3,6,7,7a-hexahydro-α(R)-methyl-9-oxo-7,3a-(epoxymethano)-3aH-indene-1-acetate 
• 85585-60-0 rel-(1S,5S,8R)-8-iodo-1-(3-oxopropyl)-6-oxabicyclo<3.2.1>oct-2-en-7-one 
• 112946-31-3 rel-(1R,3aR,4R,7R,7aS)-1-<2-<<(1,1-Dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,7,7a-hexahydro-4-hydroxy-7,3a-(epoxymethano)-3aH-inden-9-one 
• 112946-30-2 rel-(1R,3aR,4S,5R,7R,7aS)-1-<2-<<(1,1-Dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-4,5-epoxy-1,2,3,4,5,6,7,7a-octahydro-7,3a-(epoxymethano)-3aH-inden-9-one 
• 99474-54-1 rel-(1R,3aS,7R,7aS)-1-<2-<<(1,1-Dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,6,7,7a-hexahydro-7,3a-(epoxymethano)-3aH-inden-9-one 
• 99474-52-9 rel-(1S,3aS,7R,7aS)-1,2,3,6,7,7a-Hexahydro-α(S)-methyl-9-oxo-7,3a-(epoxymethano)-3aH-indene-1-acetic acid 
• 99474-48-3 rel-<1R(E),5R,8R>-Ethyl 5-(8-iodo-7-oxo-6-oxabicyclo<3.2.1>oct-2-en-1-yl)-2-methyl-2-pentenoate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 99474-53-0 rel-(1R,3aS,7R,7aS)-1-<2-Hydroxy-1(S)-methylethyl>-1,2,3,6,7,7a-hexahydro-7,3a-(epoxymethano)-3aH-inden-9-one 
• 88185-17-5 2,5-dimethoxybenzylmagnesium chloride 
• 112946-33-5 rel-(1R,3aR,7aS)-Methyl 1-<2-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,5,6,7,7a-octahydro-4-oxo-3aH-indene-3a-carboxylate 

Downstream Products

• 112946-37-9 rel-(1S,3aR,7aS)-1-<2-<<(1,1-Dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-3a-formyl-1,2,3,6,7,7a-hexahydro-4-<(2,5-dimethoxyphenyl)methyl>-3aH-indene 
• 112946-38-0 (1S,6R,7R,8R)-2-(2,5-Dimethoxy-benzyl)-11-methoxy-8-methyl-10-oxa-tricyclo[5.4.2.0^1,6]tridec-2-ene 
• 112968-87-3 rel-(1S,3aR,7aS)-Methyl 1-<2-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,6,7,7a-hexahydro-4-<(2,5-dimethoxyphenyl)methyl>-3aH-indene-1-carboxylate 
• 112946-35-7 rel-(1S,3aR,7aS)-Methyl 1-<2-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,5,6,7,7a-octahydro-4(E)-<(2,5-dimethoxyphenyl)methylene>-3aH-indene-1-carboxylate 
• 112968-88-4 rel-(1S,3aR,7aS)-1-<2-<<(1,1-Dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,6,7,7a-hexahydro-3a-(hydroxymethyl)-4-<(2,5-dimethoxyphenyl)methyl>-3aH-indene 
• 112946-36-8 rel-(1S,3aR,7aS)-1-<2-<<(1,1-Dimethylethyl)dimethylsilyl>oxy>-1(S)-methylethyl>-1,2,3,4,5,6,7,7a-octahydro-3a-(hydroxymethyl)-4(E)-<(2,5-dimethoxyphenyl)methylene>-3aH-indene 

Relevant articles and documents

Free-Radical Cyclizations: Application to the Total Synthesis of dl-Pleurotin and dl-Dihydropleurotin Acid

Total syntheses of the antitumor antibiotic pleurotin (1) and dihydropleurotin acid (2) are described.Early stages of the synthesis feature the construction of a trans perhydroindan substructure using a stereoselective free-radical cyclization, and the final stage of the synthesis involves the biomimetic conversion of dihydropleurotin acid (2) to pleurotin (1).